Article
Dermatology
A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, G. Avila Valle, S. Barbarot, T. Bieber, H. A. Brough, P. Calzavara Pinton, S. Christen-Zach, M. Deleuran, M. Dittmann, C. Dressler, A. H. Fink-Wagner, N. Fosse, K. Gaspar, L. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, C. G. Mortz, A. Nast, U. Nygaard, M. Redding, E. M. Rehbinder, J. Ring, M. Rossi, E. Serra-Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, C. Flohr
Summary: The evidence- and consensus-based guideline on atopic eczema, developed according to the EuroGuiDerm Guideline and Consensus Statement Development Manual, involves the participation of 29 experts from 12 European countries. The first part of the guideline provides general information, guidance, and detailed information on systemic treatment options, including conventional immunosuppressive drugs, biologics, and janus kinase inhibitors. The second part will cover other aspects of treatment.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Review
Pharmacology & Pharmacy
Yuliya Lytvyn, Asfandyar Mufti, Abrahim Abduelmula, Muskaan Sachdeva, Khalad Maliyar, Jorge R. Georgakopoulos, Jensen Yeung
Summary: Atopic dermatitis is a common skin condition with limited treatment options. Janus kinase inhibitors have been shown to be effective and safe for treating moderate-to-severe atopic dermatitis. Awareness of the clinical evidence is important for dermatologists to improve patient outcomes.
Review
Biochemistry & Molecular Biology
Jamie Afghani, Claudia Traidl-Hoffmann, Philippe Schmitt-Kopplin, Matthias Reiger, Constanze Mueller
Summary: Atopic eczema is an inflammatory skin disorder that affects approximately 20% of children worldwide, and early onset can lead to other allergic diseases. Metabolomics can be used to observe the mechanisms of this disease and potentially discover new drug targets.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Letter
Dermatology
Nicole S. Stefanko, Victor L. Quan, Raj Chovatiya
Summary: This study investigates the diagnostic delay in an autoimmune skin disease. The use of C3d and C4d immunohistochemistry is found to be a valuable tool in the diagnosis of inflammatory skin diseases.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Review
Allergy
Raj Chovatiya, Amy S. Paller
Summary: Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options. Recent studies have shown that both topical and systemic Janus kinase (JAK) inhibitors hold promise in treating AD, with further research needed to fully understand their efficacy and safety.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Allergy
Anne Birgitte Simonsen, Jojo Biel-Nielsen Dietz, Jeanne Duus Johansen
Summary: This study aimed to explore the epidemiology, aetiology and severity of hand eczema (HE) among Danish adolescents. The study found a high prevalence of HE among Danish adolescents, raising concerns about this significant clinical problem.
CONTACT DERMATITIS
(2023)
Review
Immunology
Paola Facheris, Jane Jeffery, Ester Del Duca, Emma Guttman-Yassky
Summary: Atopic dermatitis (AD) is a complex and heterogeneous inflammatory skin disease. Different phenotypes of AD based on patient characteristics have been defined, emphasizing the need for personalized treatment. Advances in understanding AD pathogenesis have led to an expansion in therapeutic options. Biomarkers in clinical studies are helping to clarify the role of cytokines and immune pathways in AD and enable personalized medicine. This review discusses changes in the understanding and treatment of AD, highlighting the scientific rationale behind targeted treatments and presenting recent clinical efficacy data.
CELLULAR & MOLECULAR IMMUNOLOGY
(2023)
Review
Medicine, General & Internal
Justin Choi, Nishadh Sutaria, Youkyung Sophie Roh, Zachary Bordeaux, Martin P. Alphonse, Shawn G. Kwatra, Madan M. Kwatra
Summary: The complexity of atopic dermatitis poses a challenge in selecting an appropriate mouse model, as no single model can fully replicate all aspects of the human condition. Recent evidence has identified distinct endotypes of AD, characterized by unique patterns of inflammation involving Th1, Th2, Th17, and Th22 axes. While all AD mouse models consistently show Th2 inflammation, only some also exhibit Th17 and/or Th22 induction, highlighting the need for a closer evaluation of their immunological signature to enhance their relevance to human AD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Alice Plant, Michael R. Ardern-Jones
Summary: Atopic dermatitis is a common inflammatory skin disease characterized by itch, which can significantly impact quality of life and persist into adulthood. General physicians must recognize the disease to differentiate acute flares from other conditions, such as eczema herpeticum and allergic reactions. While current treatments focus on broad spectrum immunomodulation, advancements in understanding the disease's pathophysiology have expanded treatment options, with promising new drugs offering potential for more effective and safe therapies in the future.
Review
Medicine, Research & Experimental
Marlenne Marisol Garcia-Reyes, Luis Carlos Zumaya-Perez, Rodolfo Pastelin-Palacios, Mario Adan Moreno-Eutimio
Summary: This meta-analysis examines the levels of TSLP in AD patients and controls. The findings suggest that TSLP levels are significantly higher in the AD group, indicating its critical role in the development of AD.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Julius Garcia Gatmaitan, Ji Hyun Lee
Summary: Atopic dermatitis is a complex condition with various factors affecting its treatment and management. In addition to conventional therapies, new drugs targeting specific molecular pathways in atopic dermatitis are being developed to address its complex pathophysiology. The efficacy of these drugs depends on factors such as genotype, environmental triggers, microbiome-derived signals, and immune responses. This review highlights the challenges and recent pharmacological developments in atopic dermatitis, aiming for a more personalized therapeutic approach.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Petra Pavel, Stefan Blunder, Verena Moosbrugger-Martinz, Peter M. Elias, Sandrine Dubrac
Summary: Atopic dermatitis is a chronic inflammatory skin disease influenced by both genetic and environmental factors. Alterations of the epidermal barrier and lipid abnormalities play crucial roles in the development and inflammation of the disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Editorial Material
Medicine, General & Internal
Hui Ling Foo, Hong Liang Tey
Summary: Recent research on atopic dermatitis has identified it as a heterogeneous inflammatory skin disorder with different immune polarisation and genetic mutations, leading to the development of endotype-driven management. A practical approach has been proposed to classify patients into intrinsic and extrinsic phenotypes for targeted management based on underlying endotypes.
ANNALS ACADEMY OF MEDICINE SINGAPORE
(2021)
Article
Allergy
Simon de Lusignan, Helen Alexander, Conor Broderick, John Dennis, Andrew McGovern, Claire Feeney, Carsten Flohr
Summary: There is an increased risk of developing autoimmune conditions among individuals newly diagnosed with AD, especially those with more severe AD.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Dermatology
Raj Chovatiya, Jonathan I. Silverberg
Summary: DESCRIBE-AD is a novel framework that standardizes the assessment of atopic dermatitis (AD), capturing multiple factors such as morphology, disease progression, symptom severity, comorbidities, treatment response, lesion intensity, disease burden, and lesion extent. It provides a comprehensive approach to describe the heterogeneity of AD and guide treatment decisions.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
